ReviewGut microbes
The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health.
Review in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 496 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
496 citing papers in PubMed, 1 synthesis or guideline pooled it, 764 citations in OpenAlex.
- Pooled it
- Trial
- Trial
- Daily consumption of Fuzhuan brick tea improves lipid profile and vascular function associated with modulation in gut microbiota composition in healthy adults: a pilot randomized controlled trial.Frontiers in nutrition · 2026Trial
- Gut microbiota-derived metabolite isovalerylcarnitine modulates salt sensitivity of blood pressure and incident hypertension: a multicenter dietary salt intervention trial.Nature communications · 2025Trial
- Trial
- Precise probiotic therapy: Advances, bottlenecks, and the road to microbiome-informed nutrition.Gut microbes · 2026Review
- Article
- Gut microbial allies and adversaries in SARS-CoV-2 infection.Current research in microbial sciences · 2026Article
- Toxic Metals and Metalloids Exposure and the Gut-Cardiometabolic Axis: A Narrative Review of Microbiome Dysbiosis, Gut Barrier Dysfunction, and Metabolic Inflammation.Cardiovascular toxicology · 2026Review
- Identification of serum metabolites associated with the EAT-Lancet planetary health diet, and their mediating role in weight status and weight changes in adults.European journal of nutrition · 2026Article
- Gut Microbiome and Fecal Metabolome Analysis Reveal Potential Non-Invasive Biomarkers For Acute Myocardial Infarction.Probiotics and antimicrobial proteins · 2026Article
- Gut microbial alterations and functional shifts in patients with hypertriglyceridemia: insights from a northwestern Chinese metagenomic study.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Microbial Legacy: Mycobacterium vaccae ATCC 15483Molecular psychiatry · 2026Article
- Gut microbiota‑immune crosstalk in recurrent pregnancy loss: Mechanisms and therapeutic perspectives (Review).Molecular medicine reports · 2026Review
- Relationship Between Hypovitaminosis C, Obesity, and Features of Metabolic Syndrome-A Narrative Review.Nutrition reviews · 2026Review
- Modulation of the gut microbiota by traditional Chinese medicine to attenuate chemotherapy-induced toxicity in gastric cancer: a review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Gut Microbiome Diversity, Functional Potential, and Ecological Relevance of Hottentotta tamulus.MicrobiologyOpen · 2026Article
- Diet and Atherosclerosis Prevention: Rethinking the Significance of "The Japan Diet".Journal of atherosclerosis and thrombosis · 2026Review
- The SLC-ome of membrane transport: from molecular discovery to physiology and clinical applications.Physiological reviews · 2026Review
436 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The gut microbiota plays an important role in cardio-metabolic diseases with diet being among the strongest modulators of gut microbiota composition and function. Resistant dietary carbohydrates are fermented to short-chain fatty acids (SCFAs) by the gut bacteria. Fiber and omega-3 rich diets increase SCFAs production and abundance of SCFA-producing bacteria. Likewise, SCFAs can improve gut barrier integrity, glucose, and lipid metabolism, regulate the immune system, the inflammatory response, and blood pressure. Therefore, targeting the gut microbiota with dietary strategies leading to increased SCFA production may benefit cardio-metabolic health. In this review, we provide an overview of the association between diet, SCFAs produced by the gut microbiota and cardio-metabolic diseases. We first discuss the association between the human gut microbiota and cardio-metabolic diseases, then investigate the role of SCFAs and finally explore the beneficial effects of specific dietary interventions that can improve cardio-metabolic outcomes through boosting the SCFA production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.